Tufts CSDD Study Finds Adoption of Adaptive Clinical
Trial Designs is Increasing
A new report from the Tufts Center for the Study of Drug Development (CSDD) indicates adaptive design saves time, resources and money for pharmaceutical companies and has a critical role to play in increasing product development efficiency and productivity. These findings can be applied to pharma and biotech companies of all sizes, as well as companies developing medical devices and diagnostics.
Some highlights from the report include:
- Data from leading sponsor organizations indicate that simple adaptive designs save $100M to $200M per year when applied at the portfolio level
- Evidence that simple adaptive designs should be considered part of routine clinical practice
- Strong support for the view that the use of adaptive dose-finding trials in exploratory development will become a critical step in reducing late phase attrition
- A clear statement that regulatory agencies support the use of adaptive design in both exploratory and late phase development and encourage dialogue with sponsors
Sign in or fill out the form to the right to download the free report now.
Sign in or fill out the form below to receive the Tufts CSDD R&D Senior Management Brief